Navigation Links
Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Date:11/19/2012

vascular gene therapy in the U.S., Europe, Russia and elsewhere, and the company recently filed new patent applications directed to certain improved techniques for the treatment of heart disease that are currently the subject of a Phase 3 registration trial based in Moscow, which is designed to generate additional safety and effectiveness data for the Russian Federation and other jurisdictions. Generx® (alferminogene tadenovec) is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents; and its safety and effectiveness have been the subject of clinical studies involving more than 650 patients in the U.S., Europe and elsewhere. Generx has been assigned the trade name Cardionovo™ for planned commercialization in the Russian Federation. Cardium believes that its Generx clinical database represents the largest and most complete gene therapy dossier – and is directed to a major medical indication that is a leading cause of death throughout the developed world.

"The resolution of these important reviews of our gene therapy patents, and the consistent decisions in our favor including rulings by the U.S. courts of appeal, underscore the value of our patent portfolio, which we believe reflects a breakthrough approach to the treatment of coronary heart disease," said Dr. Tyler M. Dylan-Hyde, Chief Business Officer and General Counsel of Cardium Therapeutics.

Recently-published findings demonstrate that Cardium's innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after one-time intracoronary administration of adenovector in mammalian hearts. Two consecutive but brief periods of coronary artery occlusion combined with co-administration of nitroglycerin increased both adenovector presence (measured by PCR)
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
2. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
3. Cardium to Present at Upcoming Investor Conferences
4. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
5. MedCath Announces Extension of Tolling Agreement With U.S. Department of Justice
6. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
7. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
8. Egenix, Inc. Announces New Director, John Reid
9. The Trendlines Group Announces Co-development Agreement with Endo
10. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
11. Sapio Sciences Announces Exemplar LIMS for Tablet Computers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Fla. , Aug. 26, 2014 ... under the symbol (NUUU) has two (2) wholly- ... Our two subsidiaries harness scientifically advanced technology to ... NUUU,s Renuell Int,l, Inc. is ... anti-aging skin care products that is made possible ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ... President and Chief Executive Officer at AMRI, will present ... September 8, 2014 at 8:45 a.m. ET. ... be accessed at AMRI,s Investor Relations web site at ... archived for 90 days following the live presentation. ...
(Date:8/26/2014)... Historically, drug development has faced a ... grow – high attrition rate, low productivity, patent ... regulatory hurdles and increasing concern about adverse ... the traditional business model of pharmaceutical companies is ... to find better ways to reduce operational costs ...
Breaking Biology Technology:Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... - Educators and software developers will have the ... learning process at the first annual Games+Learning+Society conference ... conference is being held by Games And Professional Practice ... Learning (ADL) Co-Lab and a group of instructors at ...
... Marquette University and UGS, a provider ... the largest in-kind contribution ever presented to Marquette University, in ... a market value it says is more than $30.5 million. ... Jim Factor's Geometric Modeling Lab in the Department of Mathematics, ...
... Assembly on Thursday passed AB 499, a proposed ban on ... would outlaw the cloning of embryos both for reproductive purposes ... the making of a cloned embryo for the purpose of ... were to become law would go up to ten years ...
Cached Biology Technology:Education conference to draw together games researchers 2
(Date:8/25/2014)... fires began as a lightning strike on August 12, 2014. ... 20% contained. There are close to 2,000 personnel ... many small fires and a number of large ones. ... account for about 100 acres. An inversion layer settled ... on August 24, keeping fire activity moderate. As the inversion ...
(Date:8/25/2014)... Many Americans need extraordinary willpower to avoid becoming obese ... too much. For members of minority groups, maintaining a ... new research led by Luis Rivera, an experimental social ... common for minorities in the United States to endure ... inferior, and that these attitudes can prevent people from ...
(Date:8/25/2014)... 2014 Nearly 1 in 6 adults worldwide may ... disorder can cause serious complications. Auriculotherapy, a form ... the outer ear, may help in managing constipation. ... that evaluated the effectiveness of auriculotherapy in treating ... a Review article in The Journal of ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2Racial and ethnic stereotypes may contribute to obesity among minorities 2
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
S-100 alpha/beta chain (8B10)...
Biology Products: